Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
作者： Mark G. Kris , Ronald B. Natale , Roy S. Herbst , Thomas J. Lynch, Jr , Diane Prager
关键词:
摘要: … 2 trial of gefitinib. We hypothesized that blocking EGFR tyrosine kinases with gefitinib would … 250-mg and 500-mg doses of gefitinib using a randomized, double-blind, phase 2 design. …
elsevier.com
sci-hub.se 参考文章(44)
R. A. Matthay, D. A. White, J. A. D. Cooper, Drug-induced pulmonary disease. Part 2: Noncytotoxic drugs. The American review of respiratory disease. ,vol. 133, pp. 488- 505 ,(1986) , 10.1164/ARRD.1986.133.2.321
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
V. Rusch, Ethan Dmitrovsky, C. Cordon-Cardo, S. Hoda, M. Zaman, Jonathan M Kurie, J. Mcintosh, J. Baselga, J. Orazem, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Research. ,vol. 53, pp. 2379- 2385 ,(1993)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)
J P O'Connell, M G Kris, R J Gralla, S Groshen, A Trust, J J Fiore, D P Kelsen, R T Heelan, R B Golbey, Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. Journal of Clinical Oncology. ,vol. 4, pp. 1604- 1614 ,(1986) , 10.1200/JCO.1986.4.11.1604
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
Carlos L. Arteaga, The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Journal of Clinical Oncology. ,vol. 19, ,(2001)
M.G Kris, R Herbst, D Rischin, P LoRusso, J Baselga, L Hammond, A Feyereislova, J Ochs, S Averbuch, Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) Lung Cancer. ,vol. 29, pp. 72- ,(2000) , 10.1016/S0169-5002(00)80233-0
Clifton F. Mountain, Revisions in the International System for Staging Lung Cancer Chest. ,vol. 111, pp. 1710- 1717 ,(1997) , 10.1378/CHEST.111.6.1710